Jeffrey B. Stavenhagen

TL;DR: In this article, a variant Fc region comprising at least one amino acid modification relative to a wild-type Fc regions was proposed, which was used for the treatment or prevention of a disease or disorder where an enhanced efficacy of effector cell function mediated by FcγR is desired.

TL;DR: In a xenograft murine model of B-cell malignancy, the greatest enhancement of an Fc-optimized anti-human B- cell mAb was accounted for by improved binding to FcgammaRIV, a unique mouse activating FcGammaR that is expressed by monocytes and macrophages but not natural killer cells.

TL;DR: In this article, a variant Fc region is defined, where the variant region comprises at least one amino acid modification relative to the wild-type Fc regions. And the modified molecules have an effector function mediated by a FcγR, such as, but not limited to, ADCC.

TL;DR: 2B6 triggered CD32B‐mediated inhibitory signalling, resulting in diminished release of inflammatory mediators by FcεRI in an in vitro allergy model or decreased proliferation of human B cells induced by B‐cell receptor stimulation.

TL;DR: The data support the clinical development of MGAH22, a chimeric anti-HER2 monoclonal antibody with specificity and affinity similar to trastuzumab, with an Fc domain engineered for increased binding to both alleles of human CD16A, and demonstrates increased activity against HER2-expressing tumors.